Drug Development

HEPT Analog Moves Forward in Preclinical Tests

Published in AIDS Weekly, July 10th, 1995

An unusual member of the family of anti-HIV-1 drugs known as HEPT derivatives has pharmacokinetic properties that may permit its use as an AIDS therapy.

The acyclic nucleoside analog 1-[(2-hyroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) and its derivatives are potent inhibitors of HIV-1. Like the diverse group of drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs), most HEPT derivatives inhibit HIV-1, but not HIV-2, reverse transcriptase (RT). In fact, HEPT and the NNRTIs are sometimes referred to as HIV-1-specific RT inhibitors. But in addition to NNRTI-like noncompetitive RT inhibition, the HEPT compounds also inhibit HIV RT by competing with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-07-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry